Beijing Beilu Pharmaceutical Hits Day High with 8.58% Surge

Beijing Beilu Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.58% on June 29, 2026. The stock reached an intraday high of CNY 7.88, marking a notable achievement for the small-cap company in the Pharmaceuticals & Biotechnology sector. In terms of performance metrics, Beijing Beilu has shown resilience over the past week, outperforming the China Shanghai Composite, which declined by 2.14%. The company's operating profit has surged by 24.59%, contributing to a robust financial outlook. Notably, the company reported a remarkable 775.5% increase in profits over the past year, despite a stock return of -18.31%. The company’s net sales for the half-year reached CNY 652.96 million, reflecting a growth rate of 21.7%. Additionally, its operating cash flow hit a record high of CNY 255.83 million. With a market capitalization of CNY 3,062 million, Beijing Beilu maintains a price-to-book ratio of 1.33 and a return on equity of 3.36%. These indicators highlight the company's current market position and operational efficiency.